SEC filing · 8-K

Spyre Therapeutics, Inc.: Material agreement

Spyre Therapeutics agreed to sell common stock in a public offering to raise approximately $350.0 million in gross proceeds.

Filed October 7, 2026

Positive for the company

What happened

On October 5, 2026, Spyre Therapeutics entered into an underwriting agreement to sell 4,117,648 shares of common stock at a public offering price of $85.00 per share.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Spyre Therapeutics, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.